Onderzoek van CVS Health toont als eerste verbeterde therapietrouw en gezondheidsresultaten voor generieke statines aan

30 september 2014

A study by researchers at CVS Health and Brigham and Women's Hospital published in the Annals of Internal Medicine, is the first to investigate whether starting on a generic versus a brand-name drug for the treatment of high cholesterol is associated with improved health outcomes. The analysis found that patients who took a generic statin were more likely to be adherent to their medication than those starting on a branded drug, and had an eight percent lower rate of the composite endpoint of cardiovascular events and death.
The main outcome measures of the study were adherence to statin therapy and health outcomes as determined by tracking hospitalizations (CVS Website, 15 september 2014).
Klik hier voor het volledige persbericht.
Klik hier voor meer informatie over het wetenschappelijke artikel.

Dit bericht is ook opgenomen in ons maandelijkse overzicht, de NVC Members-only Update. Heeft u vragen, neem dan contact met ons op via e-mail of bel: +31-(0)182-512411.